Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Notably, as these studies were largely open-label with varying intensities of lifestyle intervention and control conditions, they are better suited as evidence for strategic feasibility rather than as direct equivalents to placebo-controlled trials
Quick Answer: GLP-1 receptor agonists are being investigated for potential neuroprotective effects in Alzheimer's disease, but they are not FDA-approved for dementia prevention or treatment
Animal studies have shown that GLP-1 receptors are present on bone cells, including osteoblasts and osteoclasts, suggesting a potential direct effect on bone metabolism, though the clinical relevance in humans remains uncertain
310 Risk should be addressed through pre-operative screening and longitudinal monitoring, particularly in individuals with prior substance use and mental health disorders
US$ 23.43
US$ 21.74
,aspect=ignore)
US$ 22.46
US$ 29.40
US$ 24.52
US$ 27.71
